Aargauische Kantonalbank
VC Fund
Aarau, Switzerland
Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargauand the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Aargauische Kantonalbank invests in
Stages Aargauische Kantonalbank invests in
Countries Aargauische Kantonalbank invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.5M–$3.6M
- Series B
- $1.4M–$2.3M
Investment Focus
Industry
- Medical Device 3 (23%)
- Dental 2 (15%)
- Medical 2 (15%)
- Biopharma 2 (15%)
- Biotechnology 2 (15%)
Stage
- Series B 4 (31%)
- Seed 3 (23%)
- Series A 2 (15%)
- Angel 1 (8%)
- Funding Round 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dieter Widmer
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MESH offers robotic rebar solutions to the construction industry. We developed the world's first technology to combine formwork and reinforcement within a digital planning and fabrication process. Our technology makes it possible to produce complex or curved reinforcement cages through an automated prefabrication process. The 3D steel-meshstructure created this way serves as both formwork and reinforcement and is filled by a specific concrete mix without using conventional formwork. MESH offers building 3D concrete structures with greater material efficiency and design freedom for the construction industry. We link your computational design to the digital production of tailor-made reinforcement cages | $3.6M / Seed / Mar 26, 2026 | ||
| Aliunid is a cleantech startup that records, optimizes, and controls energy flows using real-time data. | Seed / May 17, 2022 | ||
| ELDICO Scientific AG (The Electron Diffraction Company) is a Swiss hardware company founded in 2019 and based in the Switzerland Innovation Park Innovaare at the Paul Scherrer Institute (PSI), a globally leading Swiss research institute for natural and engineering sciences. ELDICO develops, manufactures and sells novel instruments for electrondiffraction in crystallography, enabling nanocrystalline solid state analysis in the sub-micrometer range. Specific instruments are not yet available on the market today. ELDICO will be launching the first instrument specifically designed for nano-crystallographic investigations. The proof of concept was achieved in 2018 (ETH Zurich, C-CINA Basel) as part of a Nano-Argovia project of the Swiss Nanoscience Institute (SNI) on scientifically and industrially relevant samples. It was published in 2018 and awarded as a Top 5 "Breakthrough of the Year 2018" by leading scientific journal SCIENCE. In 2020, ELDICO took second place in the competition for the prestigious pioneer prize awarded by Technopark Zurich and the Zürcher Kantonalbank (ZKB). | $2.8M / Seed / Jul 29, 2021 | ||
| ELDICO Scientific AG (The Electron Diffraction Company) is a Swiss hardware company founded in 2019 and based in the Switzerland Innovation Park Innovaare at the Paul Scherrer Institute (PSI), a globally leading Swiss research institute for natural and engineering sciences. ELDICO develops, manufactures and sells novel instruments for electrondiffraction in crystallography, enabling nanocrystalline solid state analysis in the sub-micrometer range. Specific instruments are not yet available on the market today. ELDICO will be launching the first instrument specifically designed for nano-crystallographic investigations. The proof of concept was achieved in 2018 (ETH Zurich, C-CINA Basel) as part of a Nano-Argovia project of the Swiss Nanoscience Institute (SNI) on scientifically and industrially relevant samples. It was published in 2018 and awarded as a Top 5 "Breakthrough of the Year 2018" by leading scientific journal SCIENCE. In 2020, ELDICO took second place in the competition for the prestigious pioneer prize awarded by Technopark Zurich and the Zürcher Kantonalbank (ZKB). | $1.5M / Seed / May 07, 2020 | ||
| InterAx is pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health. InterAx is a Swiss biotech company, spinoff of ETH Zurich and Paul Scherrer Institute incorporated in 2016, reinventing drugdiscovery to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases. Our solution lies in the combination of in-house experimental assays, mathematical modelling and artificial intelligence to analyze and predict the physiological response of cells to drugs. We are able to describe the complex action of drug molecules in their cellular context and to guide the optimization of drug candidates to achieve a specific cellular response leading to higher efficacy and reduced side effects in humans, thus significantly accelerating drug discovery and de-risking clinical trials. | $3.5M / Jan 15, 2019 | ||
| InterAx is pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health. InterAx is a Swiss biotech company, spinoff of ETH Zurich and Paul Scherrer Institute incorporated in 2016, reinventing drugdiscovery to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases. Our solution lies in the combination of in-house experimental assays, mathematical modelling and artificial intelligence to analyze and predict the physiological response of cells to drugs. We are able to describe the complex action of drug molecules in their cellular context and to guide the optimization of drug candidates to achieve a specific cellular response leading to higher efficacy and reduced side effects in humans, thus significantly accelerating drug discovery and de-risking clinical trials. | $3M / Venture - Series Unknown / Jan 15, 2019 | ||
| Peripal manufactures and distributes a device that allows more patients to perform their Peritoneal dialysis at home. | Series A / Jul 27, 2017 | ||
| Mininavident provides a handheld navigation system for the precise implantation of dental implants. The system is miniaturized and includes a tablet computer for real time visualization. It provides a seamless integration of 3D implant planning with the actual surgery. With its practicability and increased precision, the system supports not onlythe experienced surgeon but also the general practitioner in the broad field of dental implantology. | $1.4M / Series B / Mar 20, 2015 | ||
| PADI Instructors have safely guided divers below the surface for over 50 years. Teaching the world's most popular dive curriculum, they transform lives, and open hearts and minds to the hidden beauty of nature's creation and our obligation to protect it. | $1.2M / Angel / Feb 02, 2015 | ||
| Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, with a US office in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix® WAVEsystemprovides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma. Engineered around the proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix® WAVEsystem delivers high-quality kinetic data across a broader range of samples than traditional SPR equipment. | $3.5M / Series A / Nov 20, 2013 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Aargauische Kantonalbank invest in?
Aargauische Kantonalbank invests primarily in Medical Device, Dental and Medical startups, most often at Series B and Seed stage. Most of the 13 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Aargauische Kantonalbank's check size?
Aargauische Kantonalbank typically joins rounds of $1.5M–$3.6M at Seed and $1.4M–$2.3M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aargauische Kantonalbank participates in.
How do I contact Aargauische Kantonalbank?
Public channels for Aargauische Kantonalbank include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aargauische Kantonalbank?
The team at Aargauische Kantonalbank includes Dieter Widmer (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
